Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report

Various immune-related adverse events can frequently occur, which may be life-threatening if programmed death 1 or its ligand is blocked. Here, we report a rare case of concomitant autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis caused by atezolizumab plus chemotherapy in a patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Endo, Yoshinari, Inoue, Yusuke, Karayama, Masato, Nagata, Yasuyuki, Hozumi, Hironao, Suzuki, Yuzo, Furuhashi, Kazuki, Enomoto, Noriyuki, Fujisawa, Tomoyuki, Nakamura, Yutaro, Inui, Naoki, Suda, Takafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718484/
https://www.ncbi.nlm.nih.gov/pubmed/35005655
http://dx.doi.org/10.1016/j.jtocrr.2021.100263
_version_ 1784624737360543744
author Endo, Yoshinari
Inoue, Yusuke
Karayama, Masato
Nagata, Yasuyuki
Hozumi, Hironao
Suzuki, Yuzo
Furuhashi, Kazuki
Enomoto, Noriyuki
Fujisawa, Tomoyuki
Nakamura, Yutaro
Inui, Naoki
Suda, Takafumi
author_facet Endo, Yoshinari
Inoue, Yusuke
Karayama, Masato
Nagata, Yasuyuki
Hozumi, Hironao
Suzuki, Yuzo
Furuhashi, Kazuki
Enomoto, Noriyuki
Fujisawa, Tomoyuki
Nakamura, Yutaro
Inui, Naoki
Suda, Takafumi
author_sort Endo, Yoshinari
collection PubMed
description Various immune-related adverse events can frequently occur, which may be life-threatening if programmed death 1 or its ligand is blocked. Here, we report a rare case of concomitant autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis caused by atezolizumab plus chemotherapy in a patient with lung adenocarcinoma and autoantibodies. Dramatic and lasting tumor regression in response to only one therapy cycle was achieved. Nevertheless, this case suggests that careful management is required when using immunotherapy in patients with autoantibodies.
format Online
Article
Text
id pubmed-8718484
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-87184842022-01-06 Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report Endo, Yoshinari Inoue, Yusuke Karayama, Masato Nagata, Yasuyuki Hozumi, Hironao Suzuki, Yuzo Furuhashi, Kazuki Enomoto, Noriyuki Fujisawa, Tomoyuki Nakamura, Yutaro Inui, Naoki Suda, Takafumi JTO Clin Res Rep Case Report Various immune-related adverse events can frequently occur, which may be life-threatening if programmed death 1 or its ligand is blocked. Here, we report a rare case of concomitant autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis caused by atezolizumab plus chemotherapy in a patient with lung adenocarcinoma and autoantibodies. Dramatic and lasting tumor regression in response to only one therapy cycle was achieved. Nevertheless, this case suggests that careful management is required when using immunotherapy in patients with autoantibodies. Elsevier 2021-12-09 /pmc/articles/PMC8718484/ /pubmed/35005655 http://dx.doi.org/10.1016/j.jtocrr.2021.100263 Text en © 2021 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Case Report
Endo, Yoshinari
Inoue, Yusuke
Karayama, Masato
Nagata, Yasuyuki
Hozumi, Hironao
Suzuki, Yuzo
Furuhashi, Kazuki
Enomoto, Noriyuki
Fujisawa, Tomoyuki
Nakamura, Yutaro
Inui, Naoki
Suda, Takafumi
Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report
title Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report
title_full Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report
title_fullStr Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report
title_full_unstemmed Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report
title_short Marked, Lasting Disease Regression and Concomitantly Induced Autoimmune Hemolytic Anemia and Hemophagocytic Lymphohistiocytosis in a Patient With Lung Adenocarcinoma and Autoantibodies Receiving Atezolizumab Plus Chemotherapy: A Case Report
title_sort marked, lasting disease regression and concomitantly induced autoimmune hemolytic anemia and hemophagocytic lymphohistiocytosis in a patient with lung adenocarcinoma and autoantibodies receiving atezolizumab plus chemotherapy: a case report
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8718484/
https://www.ncbi.nlm.nih.gov/pubmed/35005655
http://dx.doi.org/10.1016/j.jtocrr.2021.100263
work_keys_str_mv AT endoyoshinari markedlastingdiseaseregressionandconcomitantlyinducedautoimmunehemolyticanemiaandhemophagocyticlymphohistiocytosisinapatientwithlungadenocarcinomaandautoantibodiesreceivingatezolizumabpluschemotherapyacasereport
AT inoueyusuke markedlastingdiseaseregressionandconcomitantlyinducedautoimmunehemolyticanemiaandhemophagocyticlymphohistiocytosisinapatientwithlungadenocarcinomaandautoantibodiesreceivingatezolizumabpluschemotherapyacasereport
AT karayamamasato markedlastingdiseaseregressionandconcomitantlyinducedautoimmunehemolyticanemiaandhemophagocyticlymphohistiocytosisinapatientwithlungadenocarcinomaandautoantibodiesreceivingatezolizumabpluschemotherapyacasereport
AT nagatayasuyuki markedlastingdiseaseregressionandconcomitantlyinducedautoimmunehemolyticanemiaandhemophagocyticlymphohistiocytosisinapatientwithlungadenocarcinomaandautoantibodiesreceivingatezolizumabpluschemotherapyacasereport
AT hozumihironao markedlastingdiseaseregressionandconcomitantlyinducedautoimmunehemolyticanemiaandhemophagocyticlymphohistiocytosisinapatientwithlungadenocarcinomaandautoantibodiesreceivingatezolizumabpluschemotherapyacasereport
AT suzukiyuzo markedlastingdiseaseregressionandconcomitantlyinducedautoimmunehemolyticanemiaandhemophagocyticlymphohistiocytosisinapatientwithlungadenocarcinomaandautoantibodiesreceivingatezolizumabpluschemotherapyacasereport
AT furuhashikazuki markedlastingdiseaseregressionandconcomitantlyinducedautoimmunehemolyticanemiaandhemophagocyticlymphohistiocytosisinapatientwithlungadenocarcinomaandautoantibodiesreceivingatezolizumabpluschemotherapyacasereport
AT enomotonoriyuki markedlastingdiseaseregressionandconcomitantlyinducedautoimmunehemolyticanemiaandhemophagocyticlymphohistiocytosisinapatientwithlungadenocarcinomaandautoantibodiesreceivingatezolizumabpluschemotherapyacasereport
AT fujisawatomoyuki markedlastingdiseaseregressionandconcomitantlyinducedautoimmunehemolyticanemiaandhemophagocyticlymphohistiocytosisinapatientwithlungadenocarcinomaandautoantibodiesreceivingatezolizumabpluschemotherapyacasereport
AT nakamurayutaro markedlastingdiseaseregressionandconcomitantlyinducedautoimmunehemolyticanemiaandhemophagocyticlymphohistiocytosisinapatientwithlungadenocarcinomaandautoantibodiesreceivingatezolizumabpluschemotherapyacasereport
AT inuinaoki markedlastingdiseaseregressionandconcomitantlyinducedautoimmunehemolyticanemiaandhemophagocyticlymphohistiocytosisinapatientwithlungadenocarcinomaandautoantibodiesreceivingatezolizumabpluschemotherapyacasereport
AT sudatakafumi markedlastingdiseaseregressionandconcomitantlyinducedautoimmunehemolyticanemiaandhemophagocyticlymphohistiocytosisinapatientwithlungadenocarcinomaandautoantibodiesreceivingatezolizumabpluschemotherapyacasereport

Ejemplares similares